REGNÂ – Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.REGN
$803.17Name : Regeneron Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $84,910,972,928.00
EPSttm : 41.46
Regeneron Pharmaceuticals, Inc.
$803.17
2.49%$19.52Float Short %
2.14
Margin Of Safety %
-8
Put/Call OI Ratio
0.65
EPS Next Q Diff
4.1
EPS Last/This Y
1.58
EPS This/Next Y
1.62
Price
803.17
Target Price
875.67
Analyst Recom
1.69
Performance Q
17.82
Relative Volume
1
Beta
0.4
Ticker: REGN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-14 | REGN | 754.53 | 0.59 | 3.06 | 56989 |
| 2026-01-15 | REGN | 741.57 | 0.59 | 2.48 | 57089 |
| 2026-01-16 | REGN | 732.85 | 0.58 | 1.13 | 57719 |
| 2026-01-20 | REGN | 733.97 | 0.61 | 1.67 | 42242 |
| 2026-01-21 | REGN | 749.27 | 0.61 | 0.81 | 42891 |
| 2026-01-22 | REGN | 755.44 | 0.61 | 0.60 | 43571 |
| 2026-01-23 | REGN | 753.66 | 0.62 | 1.18 | 44216 |
| 2026-01-26 | REGN | 762.65 | 0.60 | 0.64 | 43236 |
| 2026-01-27 | REGN | 771.53 | 0.60 | 0.95 | 44463 |
| 2026-01-28 | REGN | 751.12 | 0.61 | 0.80 | 44993 |
| 2026-01-29 | REGN | 748.96 | 0.62 | 1.51 | 45679 |
| 2026-01-30 | REGN | 741.45 | 0.63 | 0.66 | 47588 |
| 2026-02-02 | REGN | 755.26 | 0.60 | 0.89 | 44918 |
| 2026-02-03 | REGN | 759.77 | 0.60 | 1.12 | 45405 |
| 2026-02-05 | REGN | 766.63 | 0.62 | 0.72 | 45945 |
| 2026-02-09 | REGN | 780.21 | 0.61 | 2.09 | 44936 |
| 2026-02-10 | REGN | 754.31 | 0.62 | 2.78 | 45457 |
| 2026-02-11 | REGN | 777.43 | 0.66 | 0.45 | 46798 |
| 2026-02-12 | REGN | 784.04 | 0.66 | 0.49 | 47669 |
| 2026-02-13 | REGN | 803.08 | 0.65 | 0.63 | 47888 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-14 | REGN | 754.26 | -12.8 | -1346.0 | 43.18 |
| 2026-01-15 | REGN | 741.92 | -12.3 | -1388.0 | 43.18 |
| 2026-01-16 | REGN | 733.04 | -12.3 | -1370.4 | 43.18 |
| 2026-01-20 | REGN | 733.78 | -12.3 | -1316.2 | 43.18 |
| 2026-01-21 | REGN | 749.33 | -12.3 | -1232.0 | 43.18 |
| 2026-01-22 | REGN | 755.54 | -12.0 | -1285.9 | 43.18 |
| 2026-01-23 | REGN | 753.55 | -12.0 | -1331.3 | 43.18 |
| 2026-01-26 | REGN | 762.65 | -11.9 | -1270.1 | 43.18 |
| 2026-01-27 | REGN | 771.25 | -11.9 | -1273.5 | 43.18 |
| 2026-01-28 | REGN | 751.13 | -12.0 | -1476.4 | 43.18 |
| 2026-01-29 | REGN | 749.44 | -12.0 | -1378.5 | 43.18 |
| 2026-01-30 | REGN | 741.45 | -11.9 | -1413.1 | 43.18 |
| 2026-02-02 | REGN | 755.02 | -11.9 | -636.9 | 43.18 |
| 2026-02-03 | REGN | 759.18 | 13.1 | -1429.4 | 44.29 |
| 2026-02-04 | REGN | 771.20 | 13.1 | -1380.8 | 44.29 |
| 2026-02-05 | REGN | 766.63 | 11.3 | -1414.0 | 44.56 |
| 2026-02-06 | REGN | 785.51 | 11.3 | -1267.8 | 44.56 |
| 2026-02-09 | REGN | 780.28 | 11.3 | -1483.9 | 44.56 |
| 2026-02-10 | REGN | 754.91 | 11.3 | -1590.2 | 44.56 |
| 2026-02-11 | REGN | 778.97 | 11.3 | -1325.1 | 44.56 |
| 2026-02-12 | REGN | 784.03 | 11.4 | -1429.8 | 44.65 |
| 2026-02-13 | REGN | 803.17 | 11.4 | -1354.1 | 44.65 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-14 | REGN | -0.23 | -0.95 | 2.46 |
| 2026-01-15 | REGN | -0.23 | -0.95 | 2.46 |
| 2026-01-16 | REGN | -0.23 | -0.95 | 2.46 |
| 2026-01-20 | REGN | -0.23 | -1.17 | 2.46 |
| 2026-01-21 | REGN | -0.23 | -1.17 | 2.46 |
| 2026-01-22 | REGN | -0.23 | -1.17 | 0 |
| 2026-01-23 | REGN | -0.24 | -1.17 | 2.35 |
| 2026-01-26 | REGN | -0.23 | -1.08 | 2.46 |
| 2026-01-27 | REGN | -0.23 | -1.08 | 2.46 |
| 2026-01-28 | REGN | -0.23 | -1.08 | 2.26 |
| 2026-01-29 | REGN | -0.23 | -1.08 | 2.26 |
| 2026-01-30 | REGN | -0.23 | -1.08 | 2.26 |
| 2026-02-02 | REGN | -0.23 | -1.16 | 2.26 |
| 2026-02-03 | REGN | -0.23 | -1.16 | 2.26 |
| 2026-02-04 | REGN | -0.23 | -1.16 | 2.26 |
| 2026-02-05 | REGN | -0.23 | -1.16 | 2.26 |
| 2026-02-06 | REGN | -0.23 | -1.16 | 2.26 |
| 2026-02-09 | REGN | -0.23 | -0.61 | 2.25 |
| 2026-02-10 | REGN | -0.23 | -0.61 | 2.25 |
| 2026-02-11 | REGN | -0.29 | -0.61 | 2.14 |
| 2026-02-12 | REGN | -0.29 | -0.61 | 2.14 |
| 2026-02-13 | REGN | -0.29 | -0.61 | 2.14 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS​
6.57
Avg. EPS Est. Current Quarter
9.16
Avg. EPS Est. Next Quarter
10.67
Insider Transactions
-0.29
Institutional Transactions
-0.61
Beta
0.4
Average Sales Estimate Current Quarter
3455
Average Sales Estimate Next Quarter
3804
Fair Value
741.8
Quality Score
98
Growth Score
79
Sentiment Score
79
Actual DrawDown %
33.7
Max Drawdown 5-Year %
-59.7
Target Price
875.67
P/E
19.32
Forward P/E
15.24
PEG
1.38
P/S
5.92
P/B
2.72
P/Free Cash Flow
20.81
EPS
41.56
Average EPS Est. Cur. Y​
44.65
EPS Next Y. (Est.)
46.27
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
31.41
Relative Volume
1
Return on Equity vs Sector %
-13.6
Return on Equity vs Industry %
2.8
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
-0.65
EBIT Estimation
-1354.1
Regeneron Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 15410
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is based in Tarrytown, New York.
stock quote shares REGNÂ – Regeneron Pharmaceuticals, Inc. Stock Price stock today
news today REGNÂ – Regeneron Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch REGNÂ – Regeneron Pharmaceuticals, Inc. yahoo finance google finance
stock history REGNÂ – Regeneron Pharmaceuticals, Inc. invest stock market
stock prices REGN premarket after hours
ticker REGN fair value insiders trading